WeVote
Log In

Bill

Bill

SB 250

Enacting the right to try for individualized treatments act to permit a manufacturer to make an individualized investigative treatment available to a requesting patient.

2025-2026 Regular Session

Kansas permits manufacturers to provide unapproved experimental treatments directly to terminally or seriously ill patients who've exhausted standard options.

Enrolled and presented to Governor on Friday, April 4, 2025
0
WeVote Research Nonpartisan
Bill Summary · SB 250

Legislative bill overview

SB 250 enacts Kansas's "right to try" law, allowing manufacturers to provide investigational treatments to patients who have exhausted conventional medical options without waiting for full FDA approval. The bill permits eligible patients to access experimental drugs, biologics, and devices directly from manufacturers under specified conditions.

Why is this important

This legislation addresses the tension between patient autonomy and regulatory safety frameworks. It enables terminally ill or seriously ill patients to pursue potentially life-saving treatments that haven't completed clinical trials, while manufacturers gain liability protections and pathway clarity. The near-unanimous passage suggests broad bipartisan support for expanding patient access to experimental therapies.

Potential points of contention

  • Safety oversight concerns: Allowing treatments outside standard FDA review processes may reduce oversight of drug efficacy and safety, potentially exposing vulnerable patients to ineffective or harmful compounds
  • Equity and access gaps: "Right to try" laws can create disparities where only wealthy patients can afford experimental treatments manufacturers choose to provide
  • Manufacturer liability protections: Broad immunity provisions may discourage rigorous testing and limit patient recourse if experimental treatments cause harm

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.